AestheticsFeatured ArticlesPhotoprotectionSkin of Color

Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals

By September 9, 2020September 14th, 2020No Comments

Featured Article

Featured Article

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Read more

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Hawasatu Dumbuya PhD, Pearl E Grimes MD, Stephen Lynch PhD, Kalli Ji PhD, Manisha Brahmachary PhD, Qian Zheng Md PhD, Charbel Bouez PhD, Janet Wangari-Talbot PhD

 

 

Visible light (400–700nm), which contributes to 45% of solar radiation, contributes to skin darkening and worsening of dyschromias, particularly in individuals with Fitzpatrick skin phototypes III and higher.

The pathogenesis of melasma is incompletely understood, which poses a challenge for disease management. Causative factors include genetics, ultraviolet (UV) radiation, cosmetics, pregnancy, hormonal therapy, phototoxic drugs, and various medications.

Currently, sunscreens provide limited protection against that spectrum. Due to their capabilities in absorbing, scattering, and reflecting visible light, topical products containing pigments and/or metal oxides can provide additional photoprotection.

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen. Expert grading and colorimetry demonstrated that the iron-oxide containing formulations significantly protected against visible light-induced pigmentation compared to untreated skin or mineral SPF 50+ sunscreen in Fitzpatrick IV individuals.

Read Full Article Now
Article Cited in this Post

Open Access Articles

The Journal of Drugs in Dermatology (JDD) presents Open Access content, unrestricted access to our original articles, award-winning case studies, clinical trial reviews and clearance updates, drugs and devices, and special content geared toward medical residents and other allied health professionals.
Articles are reviewed by the Editorial Board of renowned experts, from key opinion leaders to well-known clinicians. View our open-access dermatology articles now.
View All Open Access Articles

You May Also Like

Journal of Drugs in Dermatology JDD Podcast “Ask the Investigator” spotlight about the future of acne treatment, the ongoing battle against dyspigmentation, and how to manage cutaneous side effects of targeted cancer therapies.

Did You Miss These? Must-Listen JDD Podcasts on Acne, Dyspigmentation & Oncodermatology!

| Acne, Featured Articles, Latest News, Oncodermatology, The Latest | No Comments
Listen Now! Dermatology is always evolving, and if you haven’t caught the latest "Ask the Investigator" podcast episodes, you’re missing out on game-changing insights! Hosted by the always-engaging Dr. Adam…

From Rags to Itches: The Evolution of Topical and Systemic Options for Pruritus

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Life’s an itch sometimes….am I right? Pruritus can pick apart the fabric of one’s life as both a symptom of a primary skin disease or even as a…
The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Online Gallery

Exploring the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Online Gallery

| Featured Articles, Latest News, The Latest | No Comments
Looking for images for your next lecture or presentation? We’ve got you covered!  In dermatology, accurate diagnosis and treatment rely heavily on recognizing how conditions present across diverse skin tones.…

Leave a Reply